Complicating factors in the management of condyloma acuminata in HIV patients
DOI:
https://doi.org/10.66344/jpad.v31i4.1727Abstract
Condyloma Acuminata (CA) is an infectious disease with clinical manifestation of vegetation/ hyperkeratotic growth in the mucosal area and anogenital skin. More than 90% of CA cases are caused by infection of Human Papilloma Virus (HPV) type 6 or 11. Management of CA includes surgical and non-surgical therapy. However, the conventional therapy for CA have high recurrence rate, which ranges from 50-60%. Immunocompromised patients, including people with Human Immunodeficiency Virus (HIV) have higher recurrency rates compare to healthy people. Other matter arising in the management of CA in HIV patients is its resistance to conventional therapy. Success rate of CA therapy in HIV patients is related to the patient's immune response, low zinc levels in blood and also their CD4 levels.
References
1. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39.
2. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology.2013;445(1-2):224-31.
3. Nishijima T, Nagata N, Watanabe K, Sekine K, Tanaka S, Kishida Y, et al. HIV-1 infection, but not syphilis or HBV infection, is a strong risk factor for anorectal condyloma in Asian population: A prospective colonoscopy screening study. Int J Infect Dis.2015;37:70–6.
4. Rumah Sakit Sardjito. Sistem Informasi HIV AIDS (SIHA) Yogyakarta. 2019.
5. Wifanto S., Bobby S, Aria K. Perianal Condyloma Acuminata: Factors that Contribute to the Recurrence. New Ropanasuri Journal of Surgery.2018; 3(2):31-3.
6. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician.2004; 70:2335-42.
7. Sung JH, Ahn EJ, Oh HK, Park SH. Association of immune status with recurrent anal condylomata in human immunodeficiency virus-positive patients. J Korean Soc Coloproctol.2012;28(6):294-8.
doi:10.3393/jksc.2012.28.6.2948.
8. Panfilis D, Giuseppe; Melzani, Giulia, Mori, Giovanni, Ghidini, Alessandro, Graifemberghi, Severo. Relapses After Treatment of External Genital Warts Are More Frequent in HIV-Positive Patients Than in HIV-Negative Controls. Sex Transm Dis.2002;29(3):121-5.
9. Low AJ, Clayton T, Konate I, et al. Genital warts and infection with human immunodeficiency virus in high risk women in Burkina Faso: A Longitudinal Study. BMC Infect Dis.2011;11:20
10. Aynaud, Piron D, Barrasso R, Poveda JD. Comparison of clinical, histological, and virological symptoms of HPV in HIV-1 infected men and immunocompetent subjects. Sex Transm Inf.1998;74:32–4.
11. Human papillomavirus (HPV) infection. Dalam: Morbidity and Mortality weekly report (Recommendations and Reports);Sexual transmitted disease treatment guidelines. Centers for Disease Control and Prevention.2010;59(RR-12):69-74.
12. Association of Immune Status with Recurrent Anal Condylomata in Human Immunodeficiency Virus-Positive Patients. J Korean Soc Coloproctol.2012;28(6):294-8.
13. Horvath CA, Boulet GA, Renoux VM, Delvenne PO and Bogers JP: Mechanisms of cell entry by human papillomaviruses: An overview. Virol J.2010;7:11.
14. Venuti A, Paolini F, Nasir L, et al: Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer.2011; 10:140.
15. Horvath CA, Boulet GA, Renoux VM, Delvenne PO and Bogers JP. Mechanisms of cell entry by human papillomaviruses: An overview. Virol J.2010;7:11.
16. Faridi R, Zahra A, Khan K and Idrees M: Oncogenic potential of human papillomavirus (HPV) and its relation with cervical cancer. Virol J.2011;8:269.
17. Renoux V.M., Bisig B., Langers I., Dortu E., Clemenceau B., Thiry M., Deroanne C., Colige A., Boniver J., Delvenne P., Jacobs N. Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur. J. Immunol.2011;41:3240–52.
18. Amador-Molina A, Hernández-Valencia JF, Lamoyi E, Contreras-Paredes A, Lizano M. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses.2013;5(11):2624-42.
19. Murtiastutik D. AIDS. Dalam: Barakbah J, Lumintang H, Martodihardjo S, editors. Buku Ajar Infeksi Menular Seksual. Surabaya: Airlangga University Press; 2008. h. 211-20.
20. Kobayashi A, Greenblatt RM, Anastos K, et al. Functional atrributes of mucosal immunity in cervical intraepithelial neoplasia and effect of HIV infection. Cancer Res.2008;64:6766-74.
21. Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus–associated cancers among persons with AIDS. J Natl Cancer Inst.2008;101:1120-30.
22. Tornesello ML, Buonaguro FM, Beth-Giraldo E, et al. Human immunode® ciency virus type 1 tat gene enhances human papillomavirus early gene expression. Intervirology.1993;36:57-64.
23. Blauvelt A, Katz SI. The skin as target, vector, and effector organ in human immunode® ciency virus disease. J Invest Dermatol.1995;105:122S-126S.
24. I Arany PhD1 and S K Tyring MD PhD. Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS.1998;9:268- 71.
25. Maywald M, Wessels I, Rink L. Zinc signals and immunity. Int J Mol Sci 2017;18(10)
26. Ibs K. H. and Rink L. Zinc-altered immune function. J Nutr.2003;133:1452S–1456S.
27. Read, Scott & Obeid, Stephanie & Ahlenstiel, Chantelle & Ahlenstiel, Golo. The Role of Zinc in Antiviral Immunity. Adv Nutr.2019;10:696-710.
28. Lazear HM, Nice TJ, Diamond MS. Interferon-λ: immune functions at barrier surfaces and beyond. Immunity.2015; 43(1):15–28.
29. Raza N, Khan DA. Zinc deficiency in patients with persistent viral warts. J Coll Physicians Surg Pak.2010;20(2):83–6.
30. Madueke NM, Osaronowen EM, Samuel OO, et al. Comparative study of plasma Zinc and Selenium levels among Human Immunodeficiency Virus (HIV) positive and negative subjects. Afr J Food Sci Technol. 2015;6:253-8.
31. Baum MK, Campa A, Lai S, et al. Zinc status in human immunodeficiency virus type 1 infections and illicit drug use. Clin Infect Dis.2003;37:117-23.
32. Koch J, Neal E, Schlott M, et al. Zinc level and infections in hospitalized patients with AIDS. Nutrition.1996;12:515-8.
33. Wiraguna AAGP, Andriani PI, Adiguna MS. Comparison of Plasma Zinc Levels Among HIV+ and HIV- Subjects Infected with Condyloma Acuminata. Asian Pac J Cancer Prev.2019;20(3):943‐9.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Nita Damayanti, Devi A Susetiati
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
